发布求助
文献互助 智能选刊 最新文献

Hepatic Oncology最新文献

筛选
英文 中文
Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. 肝细胞癌的全身治疗:从索拉非尼到联合治疗。
IF 5
Hepatic Oncology Pub Date : 2020-05-28 DOI: 10.2217/hep-2020-0004
Christoph Roderburg, Burcin Özdirik, Alexander Wree, Münevver Demir, Frank Tacke
{"title":"Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies.","authors":"Christoph Roderburg,&nbsp;Burcin Özdirik,&nbsp;Alexander Wree,&nbsp;Münevver Demir,&nbsp;Frank Tacke","doi":"10.2217/hep-2020-0004","DOIUrl":"https://doi.org/10.2217/hep-2020-0004","url":null,"abstract":"<p><p>For almost a decade, systemic therapy of advanced hepatocellular carcinoma (HCC) was limited to the tyrosine kinase inhibitor (TKI) sorafenib. Different agents including checkpoint inhibitors, TKIs and anti-VEGFR antibodies demonstrated efficacy in treatment. For the first time, the combination of atezolizumab and bevacizumab, a first-line treatment that is superior to the current standard was identified, potentially changing the way we treat HCC. In this review, we summarize current data on systemic treatment of patients with advanced HCC, focusing on combination therapies comprising immune checkpoint inhibitors, TKIs and locoregional therapies. We elucidate findings from recent trials and discuss such challenges as the lack of predictive biomarkers for identification of subgroups that will benefit from novel treatment strategies.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 2","pages":"HEP20"},"PeriodicalIF":5.0,"publicationDate":"2020-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38144704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 27
Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review. 肝间充质错构瘤和未分化胚胎性肝肉瘤:病理学回顾。
IF 5
Hepatic Oncology Pub Date : 2020-04-07 DOI: 10.2217/hep-2020-0002
Sebastiao N Martins-Filho, Juan Putra
{"title":"Hepatic mesenchymal hamartoma and undifferentiated embryonal sarcoma of the liver: a pathologic review.","authors":"Sebastiao N Martins-Filho,&nbsp;Juan Putra","doi":"10.2217/hep-2020-0002","DOIUrl":"https://doi.org/10.2217/hep-2020-0002","url":null,"abstract":"<p><p>This review highlights two rare entities that are predominantly seen in children: hepatic mesenchymal hamartoma (HMH) and undifferentiated embryonal sarcoma of the liver (UESL). HMH is a benign lesion predominantly seen in the first 2 years of life, while UESL is malignant and usually identified in patients between 6 and 10 years of age. UESL may arise in the background of HMH, and the association has been supported by similar chromosomal aberrations (19q13.4). The diagnosis of both lesions is primarily based on histologic evaluation, as the clinical and radiological features are not always typical. The clinicopathologic characteristics, pathogenesis, differential diagnoses and treatment for both lesions are discussed.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 2","pages":"HEP19"},"PeriodicalIF":5.0,"publicationDate":"2020-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38144702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 26
Welcome to Volume 7 of Hepatic Oncology. 欢迎来到肝脏肿瘤学第七卷。
IF 5
Hepatic Oncology Pub Date : 2020-04-02 DOI: 10.2217/hep-2020-0005
Caitlin Killen
{"title":"Welcome to Volume 7 of <i>Hepatic Oncology</i>.","authors":"Caitlin Killen","doi":"10.2217/hep-2020-0005","DOIUrl":"https://doi.org/10.2217/hep-2020-0005","url":null,"abstract":"","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 1","pages":"HEP14"},"PeriodicalIF":5.0,"publicationDate":"2020-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37821476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa. 患者倡导和肝癌系统治疗的未来:与Ghassan Abou-Alfa的访谈。
IF 5
Hepatic Oncology Pub Date : 2020-03-31 DOI: 10.2217/hep-2020-0008
Ghassan Abou-Alfa
{"title":"Patient advocacy and the future of systemic therapies in liver cancer: an interview with Ghassan Abou-Alfa.","authors":"Ghassan Abou-Alfa","doi":"10.2217/hep-2020-0008","DOIUrl":"https://doi.org/10.2217/hep-2020-0008","url":null,"abstract":"<p><p>Discussing the importance of patient advocacy and the advancement of systemic therapies for the treatment of liver cancer, we catch up with <i>Hepatic Oncology's</i> latest editorial board member Ghassan Abou-Alfa.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 1","pages":"HEP15"},"PeriodicalIF":5.0,"publicationDate":"2020-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37821477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
JAK/STAT signaling in hepatocellular carcinoma. JAK/STAT信号在肝细胞癌中的作用。
IF 5
Hepatic Oncology Pub Date : 2020-03-18 DOI: 10.2217/hep-2020-0001
Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh
{"title":"JAK/STAT signaling in hepatocellular carcinoma.","authors":"Justin Jit Hin Tang, Dexter Kai Hao Thng, Jhin Jieh Lim, Tan Boon Toh","doi":"10.2217/hep-2020-0001","DOIUrl":"10.2217/hep-2020-0001","url":null,"abstract":"<p><p>Liver cancer is the second most lethal cancer in the world with limited treatment options. Hepatocellular carcinoma (HCC), which accounts for more than 80% of all liver cancers, has had increasing global incidence over the past few years. There is an urgent need for novel and better therapeutic intervention for HCC patients. The JAK/STAT signaling pathway plays a multitude of important biological functions in both normal and malignant cells. In a subset of HCC, JAK/STAT signaling is aberrantly activated, leading to dysregulation of downstream target genes that controls survival, angiogenesis, stemness, immune surveillance, invasion and metastasis. In this review, we will focus on the role of JAK/STAT signaling in HCC and discuss the current clinical status of several JAK/STAT inhibitors.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 1","pages":"HEP18"},"PeriodicalIF":5.0,"publicationDate":"2020-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2020-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37821480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 63
The role of the innate immune system in the development and treatment of hepatocellular carcinoma. 先天免疫系统在肝细胞癌发展和治疗中的作用。
IF 5
Hepatic Oncology Pub Date : 2020-01-31 DOI: 10.2217/hep-2019-0007
Christoph Roderburg, Alexander Wree, Münevver Demir, Moritz Schmelzle, Frank Tacke
{"title":"The role of the innate immune system in the development and treatment of hepatocellular carcinoma.","authors":"Christoph Roderburg,&nbsp;Alexander Wree,&nbsp;Münevver Demir,&nbsp;Moritz Schmelzle,&nbsp;Frank Tacke","doi":"10.2217/hep-2019-0007","DOIUrl":"https://doi.org/10.2217/hep-2019-0007","url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Most patients present with advanced or metastatic HCC at diagnosis and face a dismal prognosis. Tyrosine kinases are the gold standard treatment for this disease but yield limited survival benefits. Immune checkpoint inhibitors that augment adaptive immunity have been tested in HCC. Complex interactions between tumor cells, lymphocytes and the tumor environment determine the efficacy of such immunotherapies. Innate immune mechanisms - known drivers of liver disease progression in pre-HCC conditions such as fibrosis or cirrhosis - may either support or counteract tumor-related immune activation. In this review, we will highlight current concepts of the role of the innate immune system in hepatocarcinogenesis and discuss their relevance for translation into clinics.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 1","pages":"HEP17"},"PeriodicalIF":5.0,"publicationDate":"2020-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2019-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37821479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 44
Updates of colorectal cancer liver metastases therapy: review on DEBIRI. 结直肠癌肝转移治疗进展:DEBIRI综述。
IF 5
Hepatic Oncology Pub Date : 2020-01-21 DOI: 10.2217/hep-2019-0010
Giammaria Fiorentini, Donatella Sarti, Roberto Nani, Camillo Aliberti, Caterina Fiorentini, Stefano Guadagni
{"title":"Updates of colorectal cancer liver metastases therapy: review on DEBIRI.","authors":"Giammaria Fiorentini,&nbsp;Donatella Sarti,&nbsp;Roberto Nani,&nbsp;Camillo Aliberti,&nbsp;Caterina Fiorentini,&nbsp;Stefano Guadagni","doi":"10.2217/hep-2019-0010","DOIUrl":"https://doi.org/10.2217/hep-2019-0010","url":null,"abstract":"<p><p>Colorectal cancer is a worldwide public health issue, presenting an advanced stage at diagnosis in more than 20% of patients. Liver metastases are the most common metastatic sites and are not indicated for resection in 80% of cases. Unresectable colorectal cancer liver metastases that are refractory to systemic chemotherapy may benefit from transarterial chembolization with irinotecan-loaded beads (DEBIRI). Several studies show the safety and efficacy of DEBIRI for the treatment of colorectal cancer liver metastases. The development of transarterial chembolization and the introduction of new embolics have contributed to better outcomes of DEBIRI. This article reviews the current literature on DEBIRI reporting its use, efficacy in terms of tumor response and survival and side effects.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"7 1","pages":"HEP16"},"PeriodicalIF":5.0,"publicationDate":"2020-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2019-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37821478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
Cytoplasmic translocation of nuclear LSD1 (KDM1A) in human hepatoma cells is induced by its inhibitors. 核LSD1 (KDM1A)在人肝癌细胞中的细胞质易位是由其抑制剂诱导的。
IF 5
Hepatic Oncology Pub Date : 2019-06-05 DOI: 10.2217/hep-2018-0008
Suemi Yabuta, Yoshihiro Shidoji
{"title":"Cytoplasmic translocation of nuclear LSD1 (<i>KDM1A</i>) in human hepatoma cells is induced by its inhibitors.","authors":"Suemi Yabuta,&nbsp;Yoshihiro Shidoji","doi":"10.2217/hep-2018-0008","DOIUrl":"https://doi.org/10.2217/hep-2018-0008","url":null,"abstract":"<p><strong>Aim: </strong>Histone-modifiable lysine-specific demethylase-1 (LSD1/KDM1A) is an oncoprotein upregulated in cancers, including hepatoma. We previously reported that the hepatoma-preventive geranylgeranoic acid (GGA) inhibits KDM1A at the same IC<sub>50</sub> as that of the clinically used tranylcypromine. Here, we report that these inhibitors induce the cytoplasmic translocation of nuclear KDM1A in a human hepatoma-derived cell line.</p><p><strong>Methods & results: </strong>Immunofluorescence studies revealed that KDM1A was cytoplasmically localized in HuH-7 cells 3 h after GGA or tranylcypromine addition. However, GGA did not affect the subcellular localization of another histone lysine-specific demethylase, KDM5A. This suggests that GGA-induced translocation is KDM1A specific.</p><p><strong>Conclusion: </strong>These data demonstrate, for the first time, that KDM1A inhibitors specifically induce the cytoplasmic translocation of nuclear KDM1A.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"6 2","pages":"HEP13"},"PeriodicalIF":5.0,"publicationDate":"2019-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2018-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37075029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
The evolving landscape of precision medicine in primary liver cancer. 原发性肝癌精准医学的发展前景。
IF 5
Hepatic Oncology Pub Date : 2019-06-04 DOI: 10.2217/hep-2019-0004
Sean P Martin, Xin Wei Wang
{"title":"The evolving landscape of precision medicine in primary liver cancer.","authors":"Sean P Martin,&nbsp;Xin Wei Wang","doi":"10.2217/hep-2019-0004","DOIUrl":"https://doi.org/10.2217/hep-2019-0004","url":null,"abstract":"The incidence of primary liver cancer (PLC) is rising faster than any other malignancy in the USA and is estimated to result in over 31,000 deaths in 2019 [1]. PLC poses a unique challenge in that the majority of patients suffer from both their malignancy and underlying liver damage which is the inciting factor for their hepatocarcinogenesis. Viral infections such as Hepatitis B and C, lifestyle choices such as heavy alcohol use and inherited genetic disorders such as primary biliary cirrhosis can all lead to underlying liver cirrhosis leaving the patient vulnerable to malignancy and without aggressive treatment options. There are multiple histologic subtypes which comprise PLC but by far the two most common are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). Interestingly, while historically treated as two distinct malignancies, there is a growing body of evidence that they may be more alike than previously thought. Classically it was believed that iCCA arose from cholangiocytes, and while the origins of HCC remained more elusive it was hypothesized that hepatic stem cells in addition to hepatocytes were implicated. More recent work reveals that both malignancies could originate from hepatocytes and more strikingly, in certain subsets of patients, share a common molecular subtype [2–4]. These commonalities shed light on the potential drivers of hepatocarcinogenesis and are the first steps of novel targeted therapies. With a more thorough understanding of these tumors, directed personalized care is possible.","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"6 2","pages":"HEP12"},"PeriodicalIF":5.0,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2019-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37075028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. 肝细胞癌系统治疗的当前选择和未来可能性。
IF 5
Hepatic Oncology Pub Date : 2019-06-04 DOI: 10.2217/hep-2019-0001
Jean-Luc Raoul, Jean-Sébastien Frenel, Judith Raimbourg, Marine Gilabert
{"title":"Current options and future possibilities for the systemic treatment of hepatocellular carcinoma.","authors":"Jean-Luc Raoul,&nbsp;Jean-Sébastien Frenel,&nbsp;Judith Raimbourg,&nbsp;Marine Gilabert","doi":"10.2217/hep-2019-0001","DOIUrl":"10.2217/hep-2019-0001","url":null,"abstract":"<p><p>Most hepatocellular carcinoma patients could not benefit from or experience disease recurrence after curative treatments. In 2007 sorafenib demonstrated efficacy in first line treatment of advanced hepatocellular carcinoma. After a decade of negative trials, in early 2019 we now have another tyrosine kinase inhibitor available in first line, lenvatinib, three other targeted therapies in second line post-sorafenib (regorafenib, cabozantinib and ramucirumab) and promising data from two immunotherapies (nivolumab and pembrolizumab). Unfortunately, no biomarkers have been identified to help guide our choice. In this short review we summarize the results of these different therapies and propose a therapeutic algorithm based on subgroup analysis. It is most likely that we will not have head-to-head comparisons in second line trials.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"6 1","pages":"HEP11"},"PeriodicalIF":5.0,"publicationDate":"2019-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/hep-2019-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37367028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 28
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信